Alzheimer

Light4life : a pivotal clinical study by REGEnLIFE to evaluate the therapeutic efficacy of its photomedical technology in Alzheimer’s disease

During the 15th edition of the CTAD (Clinical Trials on Alzheimer’s Disease) taking place from November 29 to December 2 of 2022 in San Francisco, USA, REGEnLIFE, a French company specialized in the research and development of innovative technologies in photo-medicine for the prevention and treatment of neurodegenerative diseases, presented the concept of its next clinical study, Light4life.

global-data

Aging population expected to increase the prevalent cases of Alzheimer’s disease, says GlobalData

The world’s aging population is expected to increase the prevalent cases of Alzheimer’s disease (AD). Analysis of the epidemiological trends of AD in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), determined that the total prevalent cases of AD are expected to increase from 10,604,756 cases in 2016 to 13,759,918 cases in 2026, at an annual growth rate of 2.98%, according to GlobalData, a leading data and analytics company.

Scroll to Top